JACC. Cardiovascular interventions最新文献

{"title":"Custom Fluoroscopic Hat-Marker Orientation to Optimize Commissural Alignment in the Evolut Valve","authors":"Osama Elkhateeb MD, Jeremy Wood MD, Christine Herman MD, Hussein Beydoun MD","doi":"10.1016/j.jcin.2025.06.025","DOIUrl":"10.1016/j.jcin.2025.06.025","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 18","pages":"Pages 2303-2305"},"PeriodicalIF":11.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of Intravascular Ultrasound–Defined Optimal Stent Expansion Criteria for Favorable 1-Year Clinical Outcomes","authors":"Sang-Hyup Lee MD ,&nbsp;Xiaoping Jin MD ,&nbsp;Yong-Joon Lee MD ,&nbsp;Jing Kan MD ,&nbsp;Zhen Ge MD ,&nbsp;Seung-Jun Lee MD ,&nbsp;Sung-Jin Hong MD ,&nbsp;Chul-Min Ahn MD ,&nbsp;Jung-Sun Kim MD ,&nbsp;Byeong-Keuk Kim MD ,&nbsp;Young-Guk Ko MD ,&nbsp;Donghoon Choi MD ,&nbsp;Yangsoo Jang MD ,&nbsp;Gregg W. Stone MD ,&nbsp;Gary S. Mintz MD ,&nbsp;Shao-Liang Chen MD ,&nbsp;Myeong-Ki Hong MD","doi":"10.1016/j.jcin.2025.07.024","DOIUrl":"10.1016/j.jcin.2025.07.024","url":null,"abstract":"<div><h3>Background</h3><div>Robust evidence on optimal stent expansion using intravascular ultrasound (IVUS) is still lacking.</div></div><div><h3>Objectives</h3><div>The aim of this study was to validate the impact of different criteria for IVUS-defined optimal stent expansion on 1-year clinical outcomes after percutaneous coronary intervention (PCI).</div></div><div><h3>Methods</h3><div>Individual patient data from 3 randomized trials were aggregated for this analysis. Patients (n = 6,290) were classified into 3 groups: optimized PCI by IVUS, nonoptimized PCI by IVUS, and angiography-guided PCI. The primary endpoint was target vessel failure (TVF) at 1 year, a composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization.</div></div><div><h3>Results</h3><div>Angiography-guided PCI was performed in 3,208 patients. Optimal stent expansion was evaluated in 3,082 patients with IVUS-guided PCI. For the absolute criterion of minimal stent area (MSA) &gt;5.5 mm² indicating optimal stent expansion, the optimized PCI group had a lower incidence of TVF (1.45% vs 3.86% vs 5.07%) compared with the nonoptimized PCI group (adjusted HR: 0.45; 95% CI: 0.26-0.75; <em>P</em> = 0.002) and the angiography-guided PCI group (adjusted HR: 0.35; 95% CI: 0.22-0.54; <em>P</em> &lt; 0.001). Relative criteria did not show a significantly different TVF incidence between the optimized and nonoptimized PCI groups. In particular, the absolute criterion of MSA &gt;5.5 mm² was associated with a significant reduction of the composite of cardiac death or target vessel myocardial infarction (0.54% in the optimized PCI group vs 1.59% in the nonoptimized PCI group; adjusted HR: 0.39; 95% CI: 0.17-0.91; <em>P</em> = 0.028).</div></div><div><h3>Conclusions</h3><div>Post-PCI stent expansion meeting an absolute criterion of MSA &gt;5.5 mm² was associated with the most favorable clinical outcomes. (Effect of Intravascular Ultrasound in Patients Receiving Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: An Individual Patient Data Meta-Analysis of IVUS-XPL, ULTIMATE and IVUS-ACS Randomized Trials; <span><span>CRD42024559794</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 18","pages":"Pages 2197-2205"},"PeriodicalIF":11.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145108657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full Issue PDF","authors":"","doi":"10.1016/S1936-8798(25)02240-X","DOIUrl":"10.1016/S1936-8798(25)02240-X","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 18","pages":"Pages I-CXVI"},"PeriodicalIF":11.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145108659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System","authors":"Raj Makkar MD ,&nbsp;Moody M. Makar MD ,&nbsp;Sabah Skaf MD ,&nbsp;Scott Chadderdon MD ,&nbsp;Howard K. Song MD ,&nbsp;Charles J. Davidson MD ,&nbsp;S. Chris Malaisrie MD ,&nbsp;D. Scott Lim MD ,&nbsp;Dale E. Fowler MD, RDCS ,&nbsp;Jacob M. Mishell MD ,&nbsp;Ivy A. Ku MD ,&nbsp;Tarun Chakravarty MD ,&nbsp;Wilson Y. Szeto MD ,&nbsp;Howard C. Herrmann MD ,&nbsp;Robert L. Smith MD ,&nbsp;Molly Szerlip MD ,&nbsp;Konstantinos P. Koulogiannis MD ,&nbsp;Leo Marcoff MD ,&nbsp;Firas Zahr MD ,&nbsp;MISCEND Study Investigators","doi":"10.1016/j.jcin.2025.08.009","DOIUrl":"10.1016/j.jcin.2025.08.009","url":null,"abstract":"<div><h3>Background</h3><div>Transcatheter mitral valve replacement (TMVR) may benefit patients at high surgical risk with mitral regurgitation (MR).</div></div><div><h3>Objectives</h3><div>The authors report 30-day and 1-year outcomes of transfemoral TMVR.</div></div><div><h3>Methods</h3><div>The MISCEND (Edwards Eos Mitral Valve Replacement: Investigation of Safety and Performance After Mitral Valve Replacement With Transcatheter Device) study is a prospective, single-arm, multicenter evaluation of the Eos transcatheter mitral valve replacement system for clinically significant, symptomatic MR. Performance and safety endpoints included device success, procedural success, 30-day rate of MR ≤1+ and 30-day composite major adverse event rate. Additional clinical, echocardiographic, functional, and quality-of-life outcomes were assessed through 1 year.</div></div><div><h3>Results</h3><div>Sixty patients (median age 79.5 years, Society of Thoracic Surgeons score 5.2%, 40% men, 43.3% with functional MR) were enrolled. Device and procedural success rates were 100.0%. The 30-day composite major adverse event rate was 43.3%, including all-cause mortality (5.0%), all-cause hospitalization (21.7%), nonelective mitral valve reintervention (1.7%), severe bleeding (28.3%), renal complication requiring unplanned dialysis or renal replacement therapy (5.0%), and major cardiac structural complication (8.3%). The rate of MR ≤1+ was 98.1% at 30 days and 100.0% at 1 year, with none/trace MR in 63.0% and 78.4% of patients, respectively. One-year outcomes showed significant improvements in 6-minute walk distance (40.5 m; 95% CI: 13.8-97.2 m; <em>P</em> = 0.003) and Kansas City Cardiomyopathy Questionnaire overall score (17.7 points; 95% CI: 11.2-27.3 points; <em>P</em> &lt; 0.01), with 86.8% of patients in NYHA functional class I/II. Rates of mortality and left ventricular pseudoaneurysm were 20.3% and 10.0%, respectively.</div></div><div><h3>Conclusions</h3><div>1-year MISCEND results demonstrate the feasibility of TMVR with the Eos system. Although safety concerns related to left ventricular pseudoaneurysm resulted in the cessation of study enrollment, learnings will inform future therapy development.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 18","pages":"Pages 2256-2266"},"PeriodicalIF":11.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anchoring an Embolized SAPIEN Valve Using an Open-Cell Stent in the Innominate Artery","authors":"Barbara A. Danek MD,&nbsp;Scott DeRoo MD,&nbsp;David Elison MD,&nbsp;Christine J. Chung MD,&nbsp;James M. McCabe MD","doi":"10.1016/j.jcin.2025.04.017","DOIUrl":"10.1016/j.jcin.2025.04.017","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 18","pages":"Pages 2283-2284"},"PeriodicalIF":11.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous Mechanical Aspiration of Transcatheter Aortic Valve Vegetation","authors":"Carlos A. Gonzalez Lengua MD ,&nbsp;Chirag Lodha MS ,&nbsp;Howard Tee MD ,&nbsp;John Lindenthal MD ,&nbsp;James Wudel MD ,&nbsp;Mauricio Cohen MD","doi":"10.1016/j.jcin.2025.05.023","DOIUrl":"10.1016/j.jcin.2025.05.023","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 18","pages":"Pages 2289-2293"},"PeriodicalIF":11.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Progression of Aortic Regurgitation After Use of Percutaneous Transaortic Left Ventricular Assist Devices","authors":"Jad Zeitoun MD,&nbsp;Clara Angulo ACS,&nbsp;Mahwash Kassi MD,&nbsp;Sachin S. Goel MD,&nbsp;Mouaz H. Al-Mallah MD, MSc,&nbsp;Dipan J. Shah MD,&nbsp;William A. Zoghbi MD,&nbsp;Maan Malahfji MD","doi":"10.1016/j.jcin.2025.07.015","DOIUrl":"10.1016/j.jcin.2025.07.015","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 18","pages":"Pages 2301-2302"},"PeriodicalIF":11.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triple-Branch Filter Protection for Aortic Arch Thrombus","authors":"Masaki Yashige MD, PhD ,&nbsp;Ryotaro Tani MD ,&nbsp;Satoaki Matoba MD, PhD ,&nbsp;Kan Zen MD, PhD","doi":"10.1016/j.jcin.2025.04.027","DOIUrl":"10.1016/j.jcin.2025.04.027","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 18","pages":"Pages 2285-2286"},"PeriodicalIF":11.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-Coated Balloons in the European Registry of Chronic Total Occlusion","authors":"Niccolò Ciardetti MD ,&nbsp;Alessio Mattesini MD, PhD ,&nbsp;Gerald S. Werner MD, PhD ,&nbsp;Iskandar Atmowihardjo MD ,&nbsp;Myron Zaczkiewicz MD ,&nbsp;Schölzel Bas MD, PhD ,&nbsp;Mohamed Ayoub MD ,&nbsp;Andrew Ladwiniec MD ,&nbsp;Joachim Weber-Albers MD ,&nbsp;Bernward Lauer MD, PhD ,&nbsp;Mihajlo Kovacic MD ,&nbsp;Rostislav Prog MD ,&nbsp;Sudhir Rathore MD ,&nbsp;Michael Behnes MD, PhD ,&nbsp;Roberto Diletti MD ,&nbsp;Omer Goktekin MD, PhD ,&nbsp;Alexander Avran MD ,&nbsp;Nicolas Boudou MD ,&nbsp;Evald H. Christiansen MD, PhD ,&nbsp;Stylianos A. Pyxaras MD, PhD ,&nbsp;Carlo Di Mario MD, PhD","doi":"10.1016/j.jcin.2025.07.036","DOIUrl":"10.1016/j.jcin.2025.07.036","url":null,"abstract":"<div><h3>Background</h3><div>Drug-coated balloons (DCBs) are increasingly used in percutaneous coronary intervention (PCI). Their application for chronic total occlusions (CTOs) is a promising option to limit stent length in diffuse disease and avoid stent underexpansion and malapposition in negatively remodeled distal vessel segments.</div></div><div><h3>Objectives</h3><div>The aim of this study was to analyze CTO PCI procedures recorded in ERCTO (European Registry of Chronic Total Occlusion) to investigate frequency of use, patient and lesion characteristics, and in-hospital outcomes of DCBs.</div></div><div><h3>Methods</h3><div>CTO cases entered into the database from 2016 to 2023 were examined and categorized according to DCB use. DCB-treated patients were further divided into 2 groups: DCBs only and DCBs in association with drug-eluting stents. To minimize the potential impact of confounding factors, 1:1 propensity score matching was applied.</div></div><div><h3>Results</h3><div>Of 40,449 CTO PCIs performed at 184 centers, DCBs were used in 2,506 (6.2%), increasing from 3.4% (n = 185 of 5,498) in 2016 to 14.9% (n = 705 of 4,722) in 2023. In-hospital complications were infrequent, but DCB-treated CTOs had significantly lower rates of pericardial tamponade (0.1% [n = 2 of 2,506] vs 0.4% [n = 169 of 37,943]; <em>P</em> = 0.006). After propensity score matching, DCB use led to reduced drug-eluting stent length (44.2 ± 36.9 mm [95% CI: 42.7-45.7 mm] vs 58.1 ± 35.9 mm [95% CI: 56.7-59.5] mm; <em>P</em> &lt; 0.001). Contrast volume was lower in the DCB-treated patients (202.4 ± 109.8 mL [95% CI: 198.1-206.7 mL] vs 211.6 ± 123 mL [95% CI: 206.8-216.4 mL]; <em>P</em> = 0.005).</div></div><div><h3>Conclusions</h3><div>The use of DCBs in CTO recanalization is increasing and is associated with a reduction in the length of stents implanted, as well as a decrease in contrast volume and a lower rate of pericardial tamponade.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 18","pages":"Pages 2209-2221"},"PeriodicalIF":11.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145108660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States","authors":"Harun Kundi MD, MMSc ,&nbsp;David J. Cohen MD, MSc ,&nbsp;Martin B. Leon MD ,&nbsp;Afek Kodesh MD ,&nbsp;Alexandra Popma MD ,&nbsp;Philipp von Stein MD ,&nbsp;Bjorn Redfors MD, PhD ,&nbsp;Lauren S. Ranard MD, MS ,&nbsp;Maria C. Alu MS ,&nbsp;Julia B. Thompson MS ,&nbsp;Jennifer von Stein MD ,&nbsp;Juan F. Granada MD ,&nbsp;Jeffrey J. Popma MD","doi":"10.1016/j.jcin.2025.06.041","DOIUrl":"10.1016/j.jcin.2025.06.041","url":null,"abstract":"<div><h3>Background</h3><div>Mitral valve intervention improves clinical outcomes in selected patients with severe mitral regurgitation; less is known about the use trends and long-term outcomes of different mitral intervention strategies in real-world patients.</div></div><div><h3>Objectives</h3><div>The aim of this study was to describe use trends in mitral valve intervention and identify factors contributing to 5-year mortality in elderly patients.</div></div><div><h3>Methods</h3><div>The fee-for-service Centers for Medicare and Medicaid Services claims database was used to identify patients ≥65 years of age hospitalized for surgical or transcatheter mitral valve intervention between January 1, 2017, and December 31, 2022. The primary outcome was 5-year mortality.</div></div><div><h3>Results</h3><div>There were 172,478 mitral valve interventions identified over the 5-year period. The number of mitral valve interventions, indexed per 100,000 Medicare Part A beneficiaries, increased by 9.2% over this period. The incidence of surgery declined by 15.7% whereas transcatheter edge-to-edge repair (M-TEER) increased by 94.8% and transcatheter mitral valve replacement (TMVR) increased by 100%. In-hospital mortality rates were 6.9% for surgery, 4.0% for TMVR, and 1.5% for M-TEER. Five-year mortality was 39.5% after surgery, 55.1% after TMVR, and 61.9% after M-TEER. Among patients at low frailty risk, 5-year mortality rates were 24.4%, 45.8%, and 52.2% for surgery, TMVR, and M-TEER, respectively; among patients at intermediate frailty risk, they were 44.8%, 62.2%, and 70.7%, respectively; among those at high frailty risk, they were 57.8%, 74.2%, and 80.6%, respectively. Quartiles of social vulnerability were incrementally associated with higher mortality.</div></div><div><h3>Conclusions</h3><div>Mitral valve interventions in elderly patients are increasing over time, driven by transcatheter therapies. Five-year mortality varied by type of intervention and was significantly influenced by frailty and social vulnerability.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 18","pages":"Pages 2241-2252"},"PeriodicalIF":11.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145108664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}